Denver Psychedelics Conference Draws National Attention

Recent advancements in psychedelic research have placed hallucinogenic drugs at the forefront of mental health treatment research. After researchers spent decades trying to find safer and more effective treatments for mental disorders, psychedelics emerged as a safe and viable treatment for mental ailments.

Studies have found that hallucinogens, including psilocybin, MDMA, and ketamine, can treat conditions such as depression and PTSD with minimal side effects. This influx of psychedelic research has brought psychedelics to the forefront of mainstream media and driven a flurry of legislative action in several regions in the country.

The upcoming Psychedelic Science conference in Denver will be the culmination of years of intense interest in psychedelics and the promise they hold as groundbreaking psychiatric treatments.  The event will be held at the Colorado Convention Center and is expected to attract 10,000 attendees from a wide range of professions. It will also feature exhibitions from around 300 exhibitors and guests such as National Institute of Mental Health director Joshua Gordon and former Texas Governor Rick Perry.

Attendees will interact with dozens of panels on everything psychedelic throughout the five-day event, with ketamine, psilocybin (magic mushrooms), DMT, ayahuasca, LSD and MDMA being the main focus of discussion.

As with the previous three iterations of the event, the 2023 Psychedelic Science Conference will be hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is one of the largest psychedelic organizations in the country and is behind several studies analyzing the effectiveness of psychedelics against various mental disorders. The organization recently partnered with the state of Colorado to study the efficacy of cannabis in treating PTSD in veterans. MAPS is also working with police in Denver to come up with strategies for responding to people on psychedelics.

Colorado has been a pioneer in psychedelic reform, decriminalizing magic mushrooms in 2022 and creating a regulated market for natural psychedelics via a ballot vote. The measure legalized the cultivation, possession and sharing of psilocin and psilocybin; it also decriminalized the possession of dimethyltryptamine, ibogaine and peyote for people aged 21 years of age and older.

However, the legislation limited the sale of psychedelics to licensed centers and gave municipalities and counties leeway to ban psychedelic healing centers if they pleased.

Industry leaders such as Cybin CEO Doug Drysdale and SVP of Clinical Operations Allison House-Gecewicz will speak at the upcoming event. Drysdale said that he is looking forward to interacting with policymakers, scientists, clinicians and other psychedelic industry stakeholders to discuss the future of the nascent psychedelic industry.

Such conferences do a great job of bringing awareness to the numerous strides that industry players such as Seelos Therapeutics Inc. (NASDAQ: SEEL) have made in their quest to develop safe therapeutics from psychedelics.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.